Can a med spa in Pennsylvania offer compounded semaglutide or tirzepatide?
Facility · part of The Practice Perimeter
Short answer
No — pharmacists may not compound drugs that are essentially copies of a commercially available product, so while branded semaglutide or tirzepatide can be obtained, a compounded version is barred unless the narrow federal 503A(b)(1)(D) exception applies.
⚠️ and the prohibition is the whole glp-1 question in one clause. “Pharmacists may not compound … drugs that are essentially copies of a commercially available drug product, except as provided in section 503a(b)(1)(D) of the Federal Food, Drug, and Cosmetic Act.” Where the branded GLP-1 can be obtained, a compounded version of it is an essential copy and Pennsylvania forbids compounding it — no quantity limit or supervision arrangement cures that.
49 Pa. Code § 27.602(2) · verified Sep 2, 2026 · regulatory monitoring, not legal advice
Related Pennsylvania rules
Pennsylvania adopts the federal compounding regime as its own, and keeps it current. “the compounding of sterile and nonsterile preparations shall be done in accordance with section 503a of the federal food, drug, and cosmetic act … federal regulations promulgated thereunder, and the current version of the usp chapters governing compounding.” “Current version” means the standard moves without the rule being reissued.
49 Pa. Code § 27.601 · verified Sep 2, 2026 · read at Cornell Legal Information Institute
The other two prohibitions bound the same rule. A pharmacist may not compound drugs “identified by the FDA as withdrawn or removed from the market because the drugs were found to be unsafe or ineffective” under 21 CFR 216.24, unless used in an IRB-approved clinical trial; nor drugs the FDA has identified in the FDCA or the Code of Federal Regulations “as products which may not be compounded”. a Pennsylvania practice’s diligence question is therefore federal: what has the FDA said about this molecule.
49 Pa. Code § 27.602(1), (3) · verified Sep 2, 2026 · read at Cornell Legal Information Institute
How other states answer this
- Alabama
- Alaska
- Arizona
- Arkansas
- California
- Colorado
- Connecticut
- Delaware
- District of Columbia
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- New Mexico
- New York
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Oregon
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Vermont
- Virginia
- Washington
- West Virginia
- Wisconsin
- Wyoming
Related Pennsylvania questions
- Is an exam required before a patient can be treated in Pennsylvania?
- Can the pre-treatment exam be done by telehealth in Pennsylvania?
- Who may perform the pre-treatment exam in Pennsylvania?
Get Pennsylvania changes as they publish
We scan the Pennsylvania legislature and licensing boards daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.
Free · unsubscribe in one click · we never sell your address
← All Pennsylvania rules and changes · MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director. Legislative data via LegiScan (CC BY 4.0).